High-dose immunoglobulin pulse therapy and risk of Covid19 infection
Therapy with hyperimmune plasma from recovered COVID19 patients has been suggested as a possible therapeutic approach. Intravenous immunoglobulins (IVIg) may harbour some protective effect. Patients undergoing IVIg or SCIg chronic treatments may have a reduced risk of contracting COVID-19 infection compared to patients receiving other immune therapies or no therapy.